Abstract

Info

Title:: A feasible study of boosting target dose for peripheral lung cancer patients undergoing stereotactic body radiotherapy: a dosimetric analysis

Author(s):: HUANG Baotian1; LIN Peixian2; 1. Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China 2. Department of Nosocomial Infection Management, the Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China

Keywords:: Keywords: peripheral lung cancer stereotactic body radiotherapy tumor dose boosting feasibility dosimetry

Abstract:: Abstract: Objective To explore the feasibility of tumor dose boosting strategy by investigating the effects of boosting the maximum dose in the target on dose-restricting parameters and normal tissue doses for peripheral lung cancer patients undergoing stereotactic body radiotherapy (SBRT), thereby providing a dosimetric reference basis for clinical treatment. Methods The CT datasets from 19 patients with peripheral lung cancer were included for treatment replanning. The dose-restricting parameters of the initial treatment plans were designed to meet the requirement of Radiation Therapy Oncology Group (RTOG) 0915 report, and then another 4 groups of plans were designed by boosting the maximum dose in the target at a 2 Gy gradient. Results The dose-restricting parameters of the 5 groups of plans met the requirement of RTOG 0915 report. The dose-restricting parameters and normal tissue doses did not differ significantly among the 5 groups of plans. However, the maximum dose in the target differed by up to 6.6 Gy (P<0.05). Conclusion Boosting the tumor dose does not affect the dose-restricting parameters and normal tissue doses for lung cancer patients undergoing SBRT. As the maximum dose is reported to be associated with local control, a strategy of tumor dose boosting is recommended in clinical practice for increasing the maximum dose in the target under the premise of meeting the dose-restricting requirement.